Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH) is a non-malignant, age-associated proliferation of the stromal and epithelial cells within the transition zone of the prostate gland. This tissue overgrowth can compress the prostatic urethra, leading to bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS).

• Hormonal Changes: Increased local conversion of testosterone to dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase, combined with age-related shifts in estrogen-to-androgen ratios.
• Aging: Senescent changes in prostatic tissue and altered growth factor signaling.
• Genetic Predisposition: Autosomal dominant inheritance patterns observed in early-onset forms (<60 years).

Under the influence of DHT, stromal and epithelial cells in the transition zone undergo hyperplasia. The expanding tissue exerts mechanical pressure on the urethra (static component), while increased smooth muscle tone mediated by alpha-1 adrenergic receptors increases outflow resistance (dynamic component). Over time, the detrusor muscle of the bladder hypertrophies to overcome this resistance, eventually leading to detrusor instability, decreased bladder compliance, and clinical LUTS.

• Prevalence: Affects approximately 50% of men by age 50, rising to nearly 90% by age

• Gender: Exclusively affects individuals with a prostate gland (biological males).
• Geography/Race: Highly prevalent worldwide, with minor variations; some studies suggest higher severity in African American populations.

• Advanced age (>40 years)
• Family history of BPH
• Obesity and metabolic syndrome
• Type 2 diabetes mellitus
• Lack of physical activity
• Cardiovascular disease

• Digital Rectal Examination (DRE): Symmetrically enlarged, smooth, firm, elastic, and non-tender prostate gland with loss of the median sulcus.
• Abdominal Palpation: Palpable, distended bladder (dullness to percussion in the suprapubic region) in cases of chronic urinary retention.
• Vitals: Usually normal, unless complicated by systemic urosepsis (tachycardia, fever, hypotension).

• Prostate Cancer: DRE reveals hard, asymmetric, irregular nodules. PSA is often disproportionately elevated.
• Urethral Stricture: History of urethral trauma, instrumentation, or urethritis; confirmed by retrograde urethrogram or cystoscopy.
• Urinary Tract Infection (UTI): Acute onset of dysuria, positive urinalysis (nitrites, leukocyte esterase), and positive urine culture.

• Acute urinary retention
• Recurrent urinary tract infections
• Bladder calculi (stones)
• Bilateral hydronephrosis leading to post-renal acute kidney injury or chronic kidney disease
• Detrusor muscle failure (myogenic bladder)

• Short-term: Excellent; symptoms improve significantly within days to weeks of medical or surgical initiation.
• Long-term: Highly manageable. Surgical interventions provide durable symptom relief for 10–15 years, with low re-operation rates ($1\% - 2\%$ annually).

• No definitive primary prevention exists.
• Secondary Prevention: Annual screening with DRE and PSA starting at age 50 (or age 45 for high-risk individuals) to monitor progression and rule out malignancy.

The following homeopathic remedies have been historically indicated for symptoms associated with Benign Prostatic Hyperplasia. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Benign Prostatic Hyperplasia.